Pharvaris (NASDAQ:PHVS) Stock Rating Reaffirmed by Morgan Stanley

Morgan Stanley restated their overweight rating on shares of Pharvaris (NASDAQ:PHVS) in a research report sent to investors on Monday, Benzinga reports. The brokerage currently has a $34.00 price target on the stock.

A number of other equities research analysts have also issued reports on PHVS. Wedbush reaffirmed an outperform rating and set a $35.00 price objective on shares of Pharvaris in a report on Thursday, April 11th. JMP Securities increased their price objective on shares of Pharvaris from $49.00 to $50.00 and gave the company a market outperform rating in a report on Thursday, April 11th.

Pharvaris Trading Up 8.9 %

Pharvaris stock opened at $20.87 on Monday. The firm has a 50 day moving average of $23.85 and a 200 day moving average of $23.33. The firm has a market capitalization of $664.50 million, a price-to-earnings ratio of -7.35 and a beta of -3.12. Pharvaris has a 12-month low of $7.93 and a 12-month high of $33.00.

Institutional Investors Weigh In On Pharvaris

Institutional investors have recently added to or reduced their stakes in the stock. Hudson Bay Capital Management LP bought a new position in shares of Pharvaris during the 3rd quarter valued at approximately $812,000. Walleye Capital LLC boosted its position in shares of Pharvaris by 15.2% during the 3rd quarter. Walleye Capital LLC now owns 81,017 shares of the company’s stock valued at $1,691,000 after acquiring an additional 10,691 shares during the last quarter. Blackstone Inc. bought a new position in shares of Pharvaris during the 4th quarter valued at approximately $2,805,000. Vivo Capital LLC bought a new position in shares of Pharvaris during the 4th quarter valued at approximately $7,994,000. Finally, Commodore Capital LP bought a new position in shares of Pharvaris during the 4th quarter valued at approximately $22,440,000.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE).